ARKRAY, Inc.（株式会社アークレイ） - Global Leader in In-Vitro Diagnostics and Diabetes Care

📢 Key Milestones (2024–2025):
   ARKRAY, Inc. reported group sales of ¥61.4 billion for FY2024 (ended October 2024). In May 2025, the company began direct sales of the GLUCOCARD series blood glucose meters and 7 related products in the Japanese market. In January 2025, the company's blood glucose test strip received NMPA renewal approval in China. In September 2024, the ARKRAY Healthcare Surat Factory in India passed a WHO prequalification inspection. The ARKRAY 4U corporate venture capital program continues with a ¥10 billion investment framework.

Company Profile (Updated April 2026)

ARKRAY, Inc. is a privately held Japanese medical device and in-vitro diagnostics (IVD) company headquartered in Kyoto, Japan. Founded in June 1960 as Kyoto Daiichi Kagaku Inc. (KDK) by Tadashi Doi, the company began as a manufacturer of optical components for infrared spectrometers before pivoting to clinical laboratory diagnostics. Today, ARKRAY is recognized as a global pioneer in diabetes care and urinalysis, with products used in hospitals, clinics, veterinary settings, home care, and sports facilities across more than 80 countries and regions.

The company operates an integrated business model encompassing research and development, manufacturing, sales and marketing, and customer services. Its global production network is anchored by the ARKRAY Factory, Inc. mother factory in Shiga, Japan, supported by manufacturing subsidiaries in the Philippines, china, USA, India, Ireland, Russia, and Europe. ARKRAY, Inc. is not publicly traded and remains a privately held corporation.

Development History:

- 1960.06: Founded as Kyoto Daiichi Kagaku Inc. (KDK) by Tadashi Doi in Fushimi-ku, Kyoto; initially produced optical components for analytical instruments

- 1963.09.26: Reorganized into a joint stock corporation

- 1964.09: Awarded the Best Small and Medium Enterprise Factory Prize

- 1970: Developed the world's first personal blood glucose meter "EYETONE", licensed to Ames Company (USA) for global distribution

- 1972: Introduced the world's first automated urine analyzer

- 1973: Developed a quantitative blood glucose monitoring system (portAble reflectance spectrophotometer), establishing the Foundation for self-monitoring of blood glucose (SMBG)

- 1983: Released the photometric glucose meter GLUCOSCOT with proprietary test strips

- 1991: Collaborated with Matsushita Electric (Panasonic) to develop the electRochemical glucose meter GLUCOCARD, a credit-card-sized device requiring only 5 µL of blood

- 1995: Unveiled the corporate brand "ARKRAY"

- 1996: Company name changed to ARKRAY, Inc. in June; established Optron Business Center China Office in Shanghai in September

- 1997: Established ARKRAY Factory predecessor entity in Shiga

- 2000.06: Officially renamed "ARKRAY, Inc."

- 2001.11: Separated marketing department to establish ARKRAY Marketing, Inc. and ARKRAY Global Business, Inc.

- 2002: ACHieved group sales of ¥50 billion; established manufacturing subsidiary in Shanghai, China

- 2004: Established ARKRAY Europe, B.V. in the Netherlands

- 2006: Opened Tokyo headquarters in Yotsuya and Kyoto headquarters at Shijo-Karasuma; established ARKRAY AMERICA, Inc. and ARKRAY USA, Inc. / ARKRAY Factory USA, Inc. in Minneapolis, Minnesota

- 2007: Awarded the Patent Strategy Excellence Enterprise recognition by the Japan Patent Office; developed the world's first self-testing glucose meter with postprandial elapsed time management

- 2009: Established ARKRAY Factory, Ltd. (Shiga) as the dedicated manufacturing subsidiary

- 2010: Celebrated 50th anniversary; completed Kyoto Research Laboratory; developed ADAMS Hybrid AH-8280 HbA1c/glucose analyzer and AUTION HYBRID AU-4050 fully automated integrated urine analyzer

- 2011: Established ARKRAY Industry, Inc. in the Philippines (Sto. Tomas, Batangas); developed ADAMS A1c HA-8181 analyzer

- 2012: Established Xi'an R&D center in China; established PT. ARKRAY in Indonesia; developed Lactate Pro 2 LT-1730 and Smart e-SMBG Android app

- 2014: Consolidated three Maryland (USA) sites into two campuses; passed FDA pre-approval inspection for the digene HC2 HPV Test with zero 483 observations

- 2015: Completed administrative renovations at Germantown, Maryland; total recent investment in Maryland reached $50 million

- 2021: Launched ARKRAY 4U corporate venture capital (CVC) program through Singapore affiliate ARKRAY & PARTNERS Pte. Ltd., with a ¥10 billion investment framework; formed strategic investment partnership with COBIO Smart Healthcare (China) and Shenzhen YHLO Biotech for AI-powered urinalysis

- 2024.10: Group sales reached ¥61.4 billion (FY2024)

- 2025.01: Blood glucose test strip (glucose oxidase method) received NMPA renewal approval in China

- 2025.05: Began direct sales of GLUCOCARD series blood glucose meters and 7 related products in Japan

Core Mission: To contribute to global healthcare through the development, manufacturing, and distribution of innovative diagnostic and monitoring products, from prevention and screening to treatment and prognosis.

Core Business & Product Portfolio

Diabetes Care (Blood Glucose Monitoring)

- GLUCOCARD Series: Blood glucose meters, test strips (Vital, Sigma, G+, etc.), and lancing devices for diabetes self-management

- ADAMS A1C: HbA1c analyzers for diabetes monitoring (new product line under development, trademark filed 2025)

- History: ARKRAY invented the world's first personal glucose meter in 1970; Japanese-made SMBG products account for approximately 20% of global supply

Urinalysis Systems

- AUTION Series: Automated and semi-automated urine chemistry analyzers, urine test strips, and sediment analysis systems

- AUTION HYBRID AU-4050: Fully automated integrated urine analyzer combining strip technology with fluorescent flow cytometry (FDA cleared, 150 samples/hour)

- History: ARKRAY introduced the world's first automated urine analyzer in 1972

Clinical Laboratory Diagnostics

- Hematology: SPOTCHEM series compact automatic cytometers and hematology analyzers

- Clinical Chemistry: Dry chemistry analyzers (SPOTCHEM EZ, etc.), hemolysis washing solutions, and biochemical reagents

- Immunological Testing: In-vitro diagnostic reagents and test kits for immunological assays

- Genetic Testing: Molecular diagnostic platforms and associated reagents

Functional Food Materials

- Health supplements and functional food products for diabetes prevention and wellness

Global Organization & Subsidiaries

Japan Operations

Group Headquarters:

- Kyoto Headquarters (Business HQ): Kyoto MiyUKi Building 10F, 689 Takenokouchi-cho, Karasuma-dori Shijo-agaru, Nakagyo-ku, Kyoto 604-8153

- Kyoto Research Laboratory: 59 Gansuin-cho, Kamigyo-ku, Kyoto 602-0008 (within Yousuien)

- Osaka Development Center: Advanced technology development

- Nagasaki Development Center: 3-5 Mansai-cho, Nagasaki (15 employees)

Major Domestic Subsidiaries:

- ARKRAY Factory, Inc.: 1480 Koji, Konan-cho, Koka-shi, Shiga 520-3306; ~264 employees; ISO 13485 certified mother factory

- ARKRAY Marketing, Inc.: 1-20-20 Yotsuya, Shinjuku-ku, Tokyo 160-0004; 234 employees; sales and distribution

- ARKRAY Infinity, Inc.: Konan-cho, Koka-shi, Shiga; 129 employees; instrument maintenance, service, used medical equipment sales, IT network systems

- Universal Healthware LLC: Kyoto; 27 employees; medical software development and web services

- Body Support Research Institute (有): Healthcare-related research

Japan Sales & Service Network (14 Offices):

Hokkaido (Sapporo), Miyagi (Sendai), Saitama, Tokyo (2 offices), Kanagawa (Yokohama), Shizuoka, Nagano, Aichi (Nagoya), Kyoto, Osaka (2 offices), Ehime (Matsuyama), Hiroshima, Fukuoka, Kagoshima

Asia-Pacific

- China: ARKRAY Factory Pinghu, Inc. (Zhejiang); ARKRAY Medical Electronics (Shanghai) Co., Ltd.; ARKRAY International Trade (Shanghai) Co., Ltd.; Beijing Sales Office; Xi'an R&D Center

- Korea: ARKRAY Global Business, Inc. Seoul Sales Office; Anyang Korean Development Center

- Singapore: ARKRAY & PARTNERS Pte. Ltd. (Regional HQ for Southeast Asia, South Asia, Oceania; CVC operator; Singapore Laboratory)

- Indonesia: PT. ARKRAY (Jakarta)

- Philippines: ARKRAY Industry, Inc. (Sto. Tomas, Batangas); ARKRAY Industry West, Inc. (Rosario, Cavite); ARKRAY Co. Ltd., Inc. (Manila sales)

- India: ARKRAY Healthcare Pvt. Ltd. (Mumbai sales); Surat Factory (Gujarat); Pune Software R&D Center

- Vietnam: Arkray Vietnam Co., Ltd. (Hanoi)

- Thailand: ARKRAY (Thailand) Co., Ltd. (Bangkok)

Europe

- Netherlands: ARKRAY Europe, B.V. (Amstelveen; regional HQ)

- Belgium: ARKRAY Europe, B.V. Belgium Branch (Brussels)

- UK: ARKRAY Factory Ltd. / Stoke-on-Trent operations

- Ireland: ARKRAY Ireland Ltd. (Dublin area)

- Italy: ARKRAY Italia S.r.l. (Monza)

- Spain: ARKRAY Espana S.A.U. (Barcelona); Portugal Branch (Lisbon)

- France: Investment in ELITECH France SAS

- Russia: ARKRAY Ltd. (Moscow)

Americas

- USA: ARKRAY USA, Inc. / ARKRAY Factory USA, Inc. (Minneapolis HQ + Germantown, MD manufacturing); ARKRAY Sciences LLC (Beverly, MA enzyme production); Redwood City, CA (bioinformatics); ARKRAY Global Business, Inc. Miami Branch

- Mexico: ARKRAY Lab Mexico, S.A. de C.V. (Mexico City)

Corporate Venture Capital: ARKRAY 4U

In November 2021, ARKRAY, Inc. launched ARKRAY 4U (ARKRAY FOR YOU), a corporate venture capital (CVC) business operated through its Singapore affiliate ARKRAY & PARTNERS Pte. Ltd.

- Investment Framework: ¥10 billion

- Target Region: Japan, Asia (including India and Israel)

- Focus: Healthcare and healthcare-related startups

- Value Proposition: Beyond financial investment, ARKRAY provides tangible and intangible business assets including R&D, manufacturing, sales, supply chain, after-sales service, quality control, and regulatory affairs expertise

- Strategic Partnerships: Includes investments in AI-powered diagnostics and digital health technologies

Financial Performance

Group Sales Trend

- FY2021 (October 2021): ¥55.6 billion

- FY2023 (October 2023): ¥61.1 billion

- FY2024 (October 2024): ¥61.4 billion

Group Employees

- November 2021: 2,501

- November 2024: 2,202

Capital Structure

- Capital: Non-public (company policy)

- Company Type: Privately held corporation (non-listed)

Company Overview

Corporate Information

Company Name: ARKRAY, Inc. (株式会社アークレイ)

Former Name: Kyoto Daiichi Kagaku Inc. (KDK) (until June 2000)

Founded: June 1960 (established as corporation September 26, 1963)

Headquarters: Kyoto Miyuki Building 10F, 689 Takenokouchi-cho, Karasuma-dori Shijo-agaru, Nakagyo-ku, Kyoto 604-8153, Japan

Kyoto Research Laboratory: 59 Gansuin-cho, Kamigyo-ku, Kyoto 602-0008 (within Yousuien)

Representative Director: Yukitoshi Yao (八尾 行俊)

Capital: Non-public (per company policy)

Employees: ~2,202 (group, as of November 1, 2024); parent company ~300

Industry: Medical Devices / In-Vitro Diagnostics (IVD)

Business: R&D, manufacturing, sales, and service of clinical testing instruments, diagnostic reagents, and test data management systems; functional food materials

Patents: 5,800+ globally

R&D Team: 200+ researchers

Website: www.arkray.co.jp/english/

Leadership

Representative Director: Yukitoshi Yao

Founder: Tadashi Doi (deceased)

Group R&D Centers: Kyoto Laboratory, Osaka Development Center, Nagasaki Development Center, Korean Development Center (Anyang), Pune Software R&D Center (India)

2026 Strategic Outlook

- Global Expansion: Continue strengthening presence in cost-sensitive emerging markets with affordable glucose meters and consumables

- Direct Sales Growth: Expand GLUCOCARD direct sales channel in Japan and leverage the model for other product lines

- Digital Innovation: Leverage AI and digitalization in diagnostic systems, supported by ARKRAY 4U CVC investments

- Product Pipeline: Advance next-generation ADAMS A1C analyzers, automated urinalysis platforms, and molecular diagnostic systems

- Manufacturing Excellence: Maintain ISO 13485 and cGMP compliance across global factory network; expand India and Philippines production capacity

- Strategic Partnerships: Deepen collaboration with COBIO (China) and other partners in AI-powered diagnostics

Contact Information

ARKRAY, Inc. (Kyoto Headquarters)

Address: Kyoto Miyuki Building 10F, 689 Takenokouchi-cho, Karasuma-dori Shijo-agaru, Nakagyo-ku, Kyoto 604-8153, Japan

TEL: +81-50-5527-9304

FAX: +81-75-431-1202

Website: www.arkray.co.jp/english/

Kyoto Research Laboratory

Address: 59 Gansuin-cho, Kamigyo-ku, Kyoto 602-0008, Japan

TEL: +81-75-662-8979

ARKRAY 4U (CVC / Singapore)

Operator: ARKRAY & PARTNERS Pte. Ltd.

Address: 71 Robinson Road, #14-01, Singapore 068895

TEL: +65-6258-3400

Website: arkray4u.com

Keywords: ARKRAY, Inc., アークレイ, Kyoto Daiichi Kagaku, KDK, Tadashi Doi, Yukitoshi Yao, IVD, diagnostic systems, diabetes care, blood glucose meter, GLUCOCARD, EYETONE, urinalysis, AUTION, hematology, SPOTCHEM, clinical chemistry, genetic testing, lancing device, Japan, Kyoto, Nakagyo-ku, Shijo, Karasuma, Kyoto Miyuki Building, private company, non-listed, ARKRAY 4U, CVC, venture capital, global subsidiaries, Philippines, China, USA, India, Europe, functional food, 614億円, 5800 patents, direct sales, NMPA, WHO prequalification